Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

US preprint study (as yet not peer reviewed) reported an increased risk of cerebral venous thrombosis in pts with COVID-19 vs pts vaccinated with Pfizer-BioNTech or Moderna vaccine (39.0 vs 4.1 per million (adjusted RR, 6.36, P<0.001).

SPS commentary:

None of the patients had received the AstraZeneca vaccine, which has been linked to cases of cerebral venous thrombosis, the risk of which the European Medicines Agency estimates at 5.0 per million people.

OSF